Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MRSN |
---|---|---|
09:32 ET | 17905 | 2.17 |
09:34 ET | 5043 | 2.2 |
09:36 ET | 871 | 2.19 |
09:38 ET | 6599 | 2.18 |
09:39 ET | 1400 | 2.18 |
09:41 ET | 1712 | 2.19 |
09:43 ET | 8692 | 2.19 |
09:45 ET | 2819 | 2.205 |
09:48 ET | 1862 | 2.2 |
09:50 ET | 2974 | 2.205 |
09:52 ET | 13759 | 2.2 |
09:54 ET | 7627 | 2.205 |
09:56 ET | 5290 | 2.205 |
09:57 ET | 5449 | 2.225 |
09:59 ET | 1450 | 2.23 |
10:01 ET | 5825 | 2.225 |
10:03 ET | 4512 | 2.23 |
10:06 ET | 1460 | 2.235 |
10:08 ET | 15645 | 2.245 |
10:10 ET | 5787 | 2.23 |
10:12 ET | 1100 | 2.235 |
10:14 ET | 4671 | 2.225 |
10:15 ET | 25773 | 2.22 |
10:17 ET | 12000 | 2.24 |
10:19 ET | 6442 | 2.2475 |
10:21 ET | 3093 | 2.245 |
10:24 ET | 10160 | 2.25 |
10:26 ET | 2650 | 2.25 |
10:28 ET | 15834 | 2.245 |
10:30 ET | 1100 | 2.245 |
10:32 ET | 13088 | 2.235 |
10:33 ET | 3240 | 2.235 |
10:35 ET | 826 | 2.23 |
10:37 ET | 4820 | 2.23 |
10:39 ET | 8836 | 2.24 |
10:42 ET | 13731 | 2.245 |
10:44 ET | 6585 | 2.235 |
10:46 ET | 7257 | 2.24 |
10:48 ET | 1548 | 2.245 |
10:50 ET | 5702 | 2.245 |
10:51 ET | 9742 | 2.26 |
10:53 ET | 480 | 2.25 |
10:55 ET | 2024 | 2.25 |
10:57 ET | 3153 | 2.25 |
11:00 ET | 6857 | 2.26 |
11:02 ET | 6474 | 2.28 |
11:04 ET | 3354 | 2.2899 |
11:06 ET | 400 | 2.28 |
11:08 ET | 4298 | 2.2801 |
11:09 ET | 1758 | 2.29 |
11:11 ET | 3053 | 2.28 |
11:13 ET | 10588 | 2.28 |
11:15 ET | 6421 | 2.27 |
11:18 ET | 400 | 2.275 |
11:20 ET | 7775 | 2.28 |
11:22 ET | 1500 | 2.28 |
11:24 ET | 100 | 2.27 |
11:26 ET | 5866 | 2.27 |
11:27 ET | 4604 | 2.275 |
11:29 ET | 500 | 2.275 |
11:31 ET | 1799 | 2.27 |
11:33 ET | 7128 | 2.28 |
11:36 ET | 2784 | 2.275 |
11:38 ET | 1900 | 2.275 |
11:40 ET | 1600 | 2.28 |
11:42 ET | 2391 | 2.265 |
11:44 ET | 2695 | 2.265 |
11:45 ET | 4380 | 2.27 |
11:47 ET | 300 | 2.26 |
11:49 ET | 1600 | 2.265 |
11:51 ET | 3485 | 2.275 |
11:54 ET | 1100 | 2.27 |
11:56 ET | 2100 | 2.27 |
11:58 ET | 1700 | 2.28 |
12:00 ET | 998 | 2.275 |
12:02 ET | 1700 | 2.27 |
12:03 ET | 10270 | 2.27 |
12:05 ET | 400 | 2.275 |
12:07 ET | 1700 | 2.275 |
12:09 ET | 5327 | 2.28 |
12:12 ET | 2711 | 2.28 |
12:14 ET | 5960 | 2.285 |
12:16 ET | 6888 | 2.28 |
12:18 ET | 100 | 2.285 |
12:20 ET | 1911 | 2.285 |
12:21 ET | 3256 | 2.285 |
12:23 ET | 2892 | 2.285 |
12:25 ET | 6203 | 2.285 |
12:27 ET | 3577 | 2.285 |
12:30 ET | 303317 | 2.275 |
12:32 ET | 13888 | 2.28 |
12:34 ET | 1700 | 2.285 |
12:36 ET | 21878 | 2.32 |
12:38 ET | 2692 | 2.315 |
12:39 ET | 6430 | 2.31 |
12:41 ET | 1500 | 2.31 |
12:43 ET | 2800 | 2.31 |
12:45 ET | 3658 | 2.31 |
12:48 ET | 4951 | 2.315 |
12:50 ET | 1700 | 2.315 |
12:52 ET | 200 | 2.31 |
12:54 ET | 1500 | 2.315 |
12:56 ET | 1400 | 2.315 |
12:57 ET | 500 | 2.31 |
12:59 ET | 3430 | 2.31 |
01:01 ET | 2500 | 2.31 |
01:03 ET | 9604 | 2.305 |
01:06 ET | 2600 | 2.31 |
01:08 ET | 4798 | 2.315 |
01:10 ET | 200 | 2.3152 |
01:12 ET | 1600 | 2.315 |
01:14 ET | 1600 | 2.315 |
01:15 ET | 1905 | 2.315 |
01:17 ET | 400 | 2.31 |
01:19 ET | 9122 | 2.305 |
01:21 ET | 2227 | 2.305 |
01:24 ET | 300 | 2.305 |
01:26 ET | 2200 | 2.305 |
01:28 ET | 2200 | 2.31 |
01:30 ET | 618 | 2.31 |
01:32 ET | 3400 | 2.3 |
01:33 ET | 6443 | 2.31 |
01:35 ET | 2000 | 2.31 |
01:37 ET | 500 | 2.31 |
01:39 ET | 2400 | 2.31 |
01:42 ET | 2492 | 2.305 |
01:44 ET | 847 | 2.3 |
01:46 ET | 1900 | 2.3 |
01:48 ET | 4023 | 2.3 |
01:50 ET | 600 | 2.3 |
01:51 ET | 1900 | 2.305 |
01:53 ET | 1393 | 2.31 |
01:55 ET | 600 | 2.3 |
01:57 ET | 2266 | 2.31 |
02:00 ET | 2500 | 2.31 |
02:02 ET | 1317 | 2.31 |
02:04 ET | 400 | 2.31 |
02:06 ET | 2238 | 2.305 |
02:08 ET | 16283 | 2.3 |
02:09 ET | 400 | 2.3 |
02:11 ET | 1600 | 2.3 |
02:13 ET | 4500 | 2.3 |
02:15 ET | 3300 | 2.3 |
02:18 ET | 18681 | 2.295 |
02:20 ET | 3300 | 2.3 |
02:22 ET | 62379 | 2.325 |
02:24 ET | 4314 | 2.34 |
02:26 ET | 12193 | 2.335 |
02:27 ET | 23861 | 2.34 |
02:29 ET | 8856 | 2.33 |
02:31 ET | 41276 | 2.33 |
02:33 ET | 5364 | 2.33 |
02:36 ET | 600 | 2.33 |
02:38 ET | 4068 | 2.34 |
02:40 ET | 5510 | 2.32 |
02:42 ET | 950 | 2.325 |
02:44 ET | 2248 | 2.325 |
02:45 ET | 3830 | 2.325 |
02:47 ET | 45151 | 2.325 |
02:49 ET | 2332 | 2.325 |
02:51 ET | 2100 | 2.325 |
02:54 ET | 8081 | 2.325 |
02:56 ET | 1851 | 2.33 |
02:58 ET | 2307 | 2.33 |
03:00 ET | 6089 | 2.33 |
03:02 ET | 11318 | 2.33 |
03:03 ET | 3100 | 2.325 |
03:05 ET | 2626 | 2.33 |
03:07 ET | 3100 | 2.33 |
03:09 ET | 8633 | 2.33 |
03:12 ET | 1800 | 2.325 |
03:14 ET | 18625 | 2.305 |
03:16 ET | 7967 | 2.315 |
03:18 ET | 2600 | 2.325 |
03:20 ET | 2000 | 2.33 |
03:21 ET | 10918 | 2.33 |
03:23 ET | 24307 | 2.315 |
03:25 ET | 2849 | 2.315 |
03:27 ET | 400 | 2.31 |
03:30 ET | 3730 | 2.315 |
03:32 ET | 2661 | 2.315 |
03:34 ET | 1777 | 2.315 |
03:36 ET | 2377 | 2.315 |
03:38 ET | 51712 | 2.295 |
03:39 ET | 7613 | 2.31 |
03:41 ET | 700 | 2.31 |
03:43 ET | 1928 | 2.305 |
03:45 ET | 3789 | 2.3 |
03:48 ET | 1600 | 2.305 |
03:50 ET | 3720 | 2.305 |
03:52 ET | 98277 | 2.29 |
03:54 ET | 47237 | 2.29 |
03:56 ET | 415110 | 2.28 |
03:57 ET | 123981 | 2.3 |
03:59 ET | 395151 | 2.31 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Mersana Therapeutics Inc | 285.1M | -2.0x | --- |
Caribou Biosciences Inc | 260.1M | -1.5x | --- |
Foghorn Therapeutics Inc. | 322.6M | -2.8x | --- |
Genfit SA | 254.9M | -8.4x | --- |
Nanobiotix SA | 331.3M | -5.4x | --- |
Metagenomi Inc | 239.0M | -3.6x | --- |
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $285.1M |
---|---|
Revenue (TTM) | $38.3M |
Shares Outstanding | 122.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.49 |
EPS | $-1.14 |
Book Value | $0.31 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | 7.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -373.05% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.